Liquid Biopsy Market Overall Study Report 2022-2028 | Biocept, Inc., Qiagen N.V., Trovagene

𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 released a new market study on 2022-2028 Liquid Biopsy Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The global research report delivers an in-depth watch on leading competitors with strategic analysis, small and macro business trends and eventualities, valuation analysis and a holistic summary within the forecast amount. Its knowledge and in-depth reports specializing in primary and secondary drivers, market share, leading segments, and geographical analysis. Further, key players, major collaborations, merger & acquisitions of trending innovation and business policies reviewed within the report. The report contains basic, secondary and advanced data referring to international standing and trend, size, share, growth, trends analysis, section, and forecasts.

The PDF for the study Request with this link: https://www.coherentmarketinsights.com/insight/request-pdf/1223

A liquid biopsy is a simple, non-invasive technique that enables clinicians to discover a range of information about a tumor, with the help of a blood sample. Some of the commercially available liquid biopsy tests for cancer are Cologurad, Guardant360, Oncotype SEQ Liquid Select, and Target Selector liquid biopsy assays. A liquid biopsy test helps detect epidermal growth factor receptor (EGFR) gene mutations, which are evident in non-small cell lung cancer (NSCLC). The process requires only 5 milliliters of blood and is way quicker than a surgical biopsy. The blood sample is processed to get 2 milliliters of plasma, which is then analyzed for determining the tumor DNA. The potential of liquid biopsies to detect disease progression or treatment resistance long before it would trigger the clinical symptoms or appear on imaging scans is a major factor driving the growth of the global liquid biopsy market.

Tissue samples removed for biopsy many not show all mutations as cancer has multiple genetic mutations, whereas liquid biopsies offer an improved chance of detecting these genetic changes. Moreover, the efficiency of liquid biopsy to improve progression and survival rates in cancer is major factor driving growth of the market. However, in December 2017, two Johns Hopkins prostate cancer researchers found differences in the results from two different liquid biopsy providers and such inconsistencies in results may hinder the growth of the market.

Rising implementation of liquid biopsy owing to its advantages over the conventional biopsy expected to boost the liquid biopsy market growth

Liquid biopsy offers efficient disease management, as well as non-invasive prenatal testing (NIPT). NIPT enables the diagnosis of potential risks of developing chromosomal abnormalities, such as Edwards’s syndrome, Down syndrome, and X and Y chromosome abnormalities. Liquid biopsy offers a complete genetic profile of the patient by providing the DNA for more than one tumor. The process is non-invasive and provides no biases in results, owing to heterogeneity of the tumor tissues. Moreover, the process requires small amount of sample and is cost and time effectiveness. Furthermore, the varied applications of liquid biopsy for the diagnosis of non-small cell lung cancer (NSCLC), breast cancer, coronary heart disease, prostate cancer, and others, is expected to propel the growth of the global market. As per a new study published in Oncology Journal in January 2018, the liquid biopsy combo involving exosomal RNA and cell-free DNA (cfDNA) improved the sensitivity of epidermal growth factor mutations in NSCLC. Furthermore, OncoCyte Corporation presented positive data from its breast cancer diagnostic test study – which was conducted in December 2017 – at the San Antonio Breast Cancer Symposium.

The global liquid biopsy market was valued at US$ 1,824.7 million in 2016 and is expected to witness a robust CAGR of 18.3% over the forecast period (2017–2025).

Manufacturers are focusing on the development of new tests, and this is expected to bolster the global liquid biopsy market growth in the near future

Some well-known players operating in the liquid biopsy market include Illumina, Inc., Roche AG, Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc., CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA.

Numerous established, as well as small players participating in the global liquid biopsy market are actively focusing on research and development of new methods of liquid biopsy through collaborations. For instance, Biodesix, a U.S.-based company, developed a novel way of extract circulating RNA from plasma in November 2017, in collaboration with Norgen Biotek. Moreover, Precipio, a U.S.-based organization, entered into a merger agreement with Transgenomic in 2017, for commercializing ICE COLD PCR (ICP) for liquid biopsies, which preferentially enriches mutant DNA sequences over wild-type DNA through selective amplification. HaploX Biotechnology, a China-based company, raised up to US$ 32 million in financing in January 2018, in order to integrate the liquid biopsy technology, artificial intelligence, and gene sequencing.

Furthermore, in May 2017, Guardant Health, Inc. raised US$ 360 million to create cancer blood tests to deploy its test for 1 million people over the next five years. Guardant Health and MD Anderson Cancer Center launched liquid biopsy partnership, in February 2017, under which Guardant is expected to help MD Anderson to build multiple on-site liquid biopsy centers. Guardant Health announced broad, long term alliance with Pfizer Oncology to support multiple clinical programs with its Guardant360 assay, in June 2017. Moreover, Guardant Health announced that it entered into separate agreements with AstraZeneca, Merck, Merck KGaA, and Darmstadt in January 2017 to develop 500 plus gene liquid biopsy panel to speed up clinical trials and drug development. Natera collaborated with Baylor Genetics to develop a non-invasive prenatal test, Vistara, in May 2017, which aided in detecting de novo mutations in single gene disorders.

𝐀𝐧 𝐨𝐮𝐭𝐥𝐢𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭:

⦿ The comprehensive market report is inclusive of a detailed summary of the competitive analysis of this industry.

⦿ Data related production sites, market share, area served, and more have been covered in the report.

⦿ The report elucidates data pertaining to the manufacturer’s product portfolio, product specifications, as well as numerous product applications.

⦿ A brief outline of the firm in question, its profit margins and pricing models are explained in the report as well.

Buy a Report of Liquid Biopsy Market Report 2022 @ https://www.coherentmarketinsights.com/insight/buy-now/1223

𝐒𝐨𝐦𝐞 𝐏𝐨𝐢𝐧𝐭𝐬 𝐟𝐫𝐨𝐦 𝐓𝐚𝐛𝐥𝐞 𝐨𝐟 𝐂𝐨𝐧𝐭𝐞𝐧𝐭:

1. Overview and Scope

1.1. Research goal & scope

1.2. Research assumptions

1.3. Research methodology

1.3.1. Primary data sources

1.3.2. Secondary data sources

1.4. Key takeaway

1.5. Stakeholders

2. Executive Summary

2.1. Market definition

2.2. Market segmentation

3. Liquid Biopsy Market Insights

3.1. Liquid Biopsy – Industry snapshot

3.1.1. Leading Companies

3.1.2. Key Companies to Watch

3.2. Liquid Biopsy – Ecosystem analysis

3.2.1. Market overview

3.2.2. Commercial Landscape

3.3. Liquid Biopsy Market Dynamics

3.3.1. – Market Forces

3.3.1.1. Market Driver Analysis

3.3.1.2. Market Restraint/Challenges analysis

3.3.1.3. Market Opportunity Analysis

3.4. Industry analysis – Porter’s five forces

3.4.1. Bargaining power of supplier

3.4.2. Bargaining power of the buyer

3.4.3. Threat of substitute

3.4.4. The threat of new entrant

3.4.5. Degree of competition

3.5. Market PEST Analysis

3.6. Market Value Chain Analysis

3.7. Industry Trends

3.8. Competitive Ranking Analysis

𝐂𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐝…………..

To speak to one of our analysts please click @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1223

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.